Bausch + Lomb Corporation (BLCO)

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

Head to Head Survey: Bausch + Lomb (NYSE:BLCO) vs. Terumo (OTCMKTS:TRUMY)

Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO)

BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Bausch + Lomb Advances Two First-in-Class Eye Health Therapies

Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript

Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal

Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript

Bausch + Lomb Q2 Earnings Call Highlights

Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S.

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States